Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy And Alternative Procoagulants

DUBLIN, January 27, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant Coagulation Factors 2015: Maturation Of Recombinant Clotting Factor Pipeline And Emergence Of Gene Therapy And Alternative Procoagulants" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

A Pipeline Landscape Analysis and Comparative Assessment of Key Players

This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents.

The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar companies, and new technology providers as half-life prolongation technologies are no longer in the focus of major interest.

A short- to mid-term outlook into the field is provided and the trends driving the future of this therapeutic segment are identified and described. Preparation of this report is based on information stored in La Merie Publishing's proprietary data base and news archive, on scientific literature, and on corporate disclosures. The data are presented, analyzed and assessed in a comprehensive manner by an experienced author with an independent view writing the fifth edition of this report series.


Key Topics Covered:

1. Executive Summary

2. Recombinant Coagulation Factor Markets
2.1 Recombinant Factor VIII (rFVIII) Product Sales and Market Size
2.2 Recombinant Factor IX (rFIX) Product Sales and Market Size
2.3 Recombinant Factor VII (rFVII) Product Sales and Market Size
2.4 Recombinant Thrombin Product Sales and Market Size
2.5 Total Recombinant Coagulation Factor Market Size

3. Pipeline Update of Recombinant Coagulation Factors
3.1 Factor VIII Pipeline Changes and Drug Profile Updates
3.2 Factor IX Pipeline Changes and Drug Profile Updates
3.3 Factor VII Pipeline Changes and Drug Profile Updates
3.4 Pipeline Update for Other Recombinant Coagulation Factors
3.5 Pipeline Update for Alternative Procoagulants
3.6 Pipeline Update for Gene & Cell Therapy
3.7 Immune Tolerance Inducing (ITI) Agents

4. Competitive Landscape Analysis of Recombinant Coagulation Factors
4.1 rFVIII Competitive Landscape Analysis
4.2 rFIX Competitive Landscape Analysis
4.3 rFVII Competitive Landscape Analysis
4.4 Competitive Landscape of Other Recombinant Coagulation Factors
4.5 Competitive Landscape of Alternative Procoagulants for Systemic Use
4.6 Competitive Landscape of Gene & Cell Therapy for Hemophilia
4.7 Immune Tolerance Inducing (ITI) Agents

5. Stakeholder Profiles
5.1 Coagulation Factor Portfolio Companies
5.2 Big Pharma & Biotech as New Entrants to Bleeding Disorder Field
5.3 Specialty Pharma as New Entrants to Hemophilia Field
5.4 Biosimilar Companies
5.5 Protein Engineering Companies
5.6 Gene & Cell Therapy Companies
5.7 RNA Companies
5.8 Immunology Companies

6. Strategic Analysis
6.1 Pipeline and Technology Overview and Trends
6.2 Short- and Mid-term Perspective of Recombinant Coagulation Factors
6.3 Key Product Profiles and Differentation Factors among Novel Products
6.4 Mid- and long-term perspective of new hemophilia treatments
6.5 Key Players in the Field

7 References

8 ADDENDUM: Development and Approval Timelines


Companies Mentioned:

• Alnylam Pharmaceuticals
• Alphamab
• Alteogen
• Amarna Therapeutics
• Apitope
• Arcturus Therapeutics
• Aryogen
• AstraZeneca
• Baxter
• Bayer HealthCare Pharmaceuticals
• Biogen Idec
• Biotest
• CSL
• Catalyst Biosciences
• Chia Tai Tiangqing Pharma Group
• Chiesi Farmaceutici
• Dimension Therapeutics
• Dong-A Pharmaceutical
• Emergent BioSolutions
• EpiVax
• Expression Therapeutics
• Generium Group
• Green Cross
• ISU Abxis
• Nektar Therapeutics
• Novo Nordisk
• Octapharma
• Opus Bio (Lentigen)
• Pfizer
• Pharming
• Pharmstandard
• REGENX Biosciences
• Roche (Chugai)
• Sangamo Biosciences
• Sanofi (Genzyme)
• Selecta Biosciences
• Shanghai Institute for Pharmaceutical Industry (SIPI, a Sinopharma company)
• Shire
• Spark Therapeutics
• Swedish Orphan Biovitrum (Sobi)
• Teijin Pharma
• The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN),
• The Medicines Company
• UCB
• Xenetic Biosciences
• uniQure

For more information visit http://www.researchandmarkets.com/research/pfd99m/recombinant

Media Contact: Laura Wood , [phone], [e-mail]